P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers

Japanese Journal of Cancer Research

Volumn 88, Issue 8, 1997, Pages 738-742

  Oka, Mikio ^a   Kounoura, Kiyoshi ^a   Narasaki, Fumihiko ^a   Sakamoto, Akira ^a   Fukuda, Minoru ^a   Matsuo, Isao ^a   Ikeda, Koki ^a   Tsurutani, Junji ^a   Ikuno, Nobuhiro ^a   Omagari, Katsuhisa ^a   Mizuta, Yohei ^a   Soda, Hiroshi ^a   Gudas, Jean M ^b   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b AMGEN INC   (United States)

Author keywords

Colon cancer; MDR1 gene; Multidrug resistance; P glycoprotein; p53

Indexed keywords

GLYCOPROTEIN P; PROTEIN P53;

ARTICLE; CANCER GRADING; CLINICAL ARTICLE; COLORECTAL CANCER; FROZEN SECTION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030826567     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00445.x     Document Type: Article

References (34)

1. Gottesman, M. M. and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427 (1993).
2. Weinstein, R. S., Kuszak, J. R., Kluskens, L. F. and Coon, J. S. P-Glycoproteins in pathology: the multidrug resistance gene family in humans. Hum. Pathol., 21, 34-48 (1990).
3. Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R. and Melamed, M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 38, 1277-1287 (1990).
4. Pastan, I. and Gottesman, M. M. Multiple-drug resistance in human cancer. N. Engl. J. Med., 316, 1388-1393 (1987).
5. Greenblatt, M. S., Bennett, W. P., Hollstein, M. and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878 (1994).
6. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W. and Galloway, D. A. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2, 72-79 (1996).
7. Hawkins, D. S., Demers, G. W. and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56, 892-898 (1996).
8. Aas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A. and Lønning, P. E. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2, 811-814 (1996).
9. Lutzker, S. G. and Levine, A. J. A functionally inactive p 53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat. Med., 2, 804-810 (1996).
10. Chin, K.-V., Ueda, K., Pastan, I. and Gottesman, M. M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science, 255, 459-462 (1992).
11. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C. and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4, 42-46 (1993).
12. Zastawny, R. L., Salvino, R., Chen, J., Benchimol, S. and Ling, V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene, 8, 1529-1535 (1993).
13. Nguyen, K. T., Liu, B., Ueda, K., Gottesman, M. M., Pastan, I. and Chin, K. V. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol. Res., 6, 71-77 (1994).
14. Rouby, S. El., Thomas, A., Costin, D., Rosenberg, C. R., Potmesil, M., Silber, R. and Newcomb, E. W. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82, 3452-3459 (1993).
15. Preudhomme, C., Lepelley, P., Vachee, A., Soenen, V., Quesnel, B., Cosson, A. and Fenaux, P. Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia, 7, 1888-1890 (1993).
16. Renninson, J., Baker, B. W., McGown, A. T., Murphy, D., Norton, J. D., Fox, B. W. and Growther, D. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Br. J. Cancer, 69, 609-612 (1994).
17. Schneider, J., Rubio, M., Barbazan, M., Rodriguez-Escudero, F. J., Seizinger, B. R. and Castresana, J. S. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J. Natl. Cancer Inst., 86, 850-855 (1994).
18. Wallner, J., Gisslinger, H., Gisslinger, B., Gsur, A., Götzl, M., Zöchbauer, S. and Pirker, R. MDR1 gene expression in chronic lymphocytic leukemia. Leuk. Lymphoma, 13, 333-338 (1994).
19. Charpin, C., Vielh, P., Duffaud, F., Devictor, B., Andrac, L., Lavaut, M. N., Allasia, C., Horschowski, N. and Piana, L. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J. Natl. Cancer Inst., 86, 1539-1545 (1994).
20. Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S., Willson, J. K. V., Hamilton, S. and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorgenesis. Cancer Res., 50, 7717-7722 (1990).
21. Weinstein, R. S., Jakate, S. M., Dominguez, J. M., Lebovitz, M. D., Koukoulis, G. K., Kuszak, J. R., Klusens, L. F., Grogan, T. M., Saclarides, T. J., Roninson, I. B. and Coon, J. S. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res., 51, 2720-2726 (1991).
22. Hall, P. A. and Lane, D. P. p53 in tumour pathology: can we trust immunohistochemistry? - revisited. J. Pathol., 172, 1-4 (1994).
23. Shi, S.-R., Chaiwun, B., Young, L., Cote, R. J. and Taylor, C. R. Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections. J. Histochem. Cytochem., 41, 1599-1604 (1993).
24. Baas, I. O., Mulder, J. R., Offerhaus, G. J. A., Vogelstein, B. and Hamilton, S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172, 5-12 (1994).
25. Purdie, C. A., O'Grady, J., Piris, J., Wyllie, A. H. and Bird, C. C. p53 expression in colorectal tumors. Am. J. Pathol., 138, 807-813 (1991).
26. van den Berg, F. M., Tigges, A. J., Schipper, M. E. I., Den Hartog-Jager, F. C. A., Kroes, W. G. M. and Walboomers, J. M. M. Expression of the nuclear oncogene p53 in colon tumors. J. Pathol., 157, 193-199 (1989).
27. Pirker, R., Wallner, J., Gsur, A., Götzl, M., Zöchbauer, S., Scheithauer, W. and Depisch, D. MDR1 gene expression in primary colorectal carcinomas. Br. J. Cancer, 68, 691-694 (1993).
28. Goldsmith, M. E., Gudas, J. M., Schneider, E. and Cowan, K. H. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J. Biol. Chem., 270, 1894-1898 (1995).
29. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. p53 mutations in human cancers. Science, 253, 49-53 (1991).
30. Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C. and Vogelstein, B. Identification of p53 as a sequence-specific DNA-binding protein. Science, 252, 1708-1710 (1991).
31. Pietenpol, J. A. and Vogelstein, B. No room at the p53 inn. Nature, 365, 17-18 (1993).
32. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. and Vogelstein, B. Definition of a consensus binding site for p53. Nat. Genet., 1, 45-49 (1992).
33. Bradley, G., Sharma, R., Rajalakshimi, S. and Ling, V. P-glycoprotein expression during tumor progression in the rat liver. Cancer Res., 52, 5154-5161 (1992).
34. Benchimol, S. and Ling, V. P-glycoprotein and tumor progression. J. Natl. Cancer Inst., 86, 814-816 (1994).